Among the neutrophil-derived proteins in feces, PMN-e, Cal, and Lf represent useful markers of disease activity in patients with UC. Using all 3 markers in a composite index may be an additional noninvasive tool for the management of ambulant patients with UC.

These results are consistent with possible short-term benefits of a comprehensive lifestyle modification program on some aspects of quality-of-life and emotional well-being, but no effects were discernable 12 months after completion of therapy. Comprehensive lifestyle modification had no effect on clinical disease variables. The generalizability of these data is limited because of the inclusion of patients with a relatively low disease activity who were interested in integrative medicine.

Objective: The T allele of the single-nucleotide polymorphism rs7903146 in TCF7L2 (transcription factor 7 like 2 gene) is associated with type 2 diabetes mellitus. The aim of this study was to analyze whether there is an allele-dosage effect on changes of insulin resistance and sensitivity indices in overweight children participating in a lifestyle intervention. Methods: We genotyped rs7903146 in 236 overweight children (mean age 10.7 years, mean body mass index (BMI) 28.1 kg/m 2 ) completing a 1-year lifestyle intervention. Degree of overweight as BMI-SDS, homeostasis model assessment for insulin resistance (HOMA-IR) and the insulin sensitivity index QUICKI were measured before and after intervention. Results: Lifestyle intervention resulted in an overweight reduction of À0.29 ± 0.02 BMI-SDS. HOMA-IR (À0.63 ± 0.22) and QUICKI ( þ 0.008 ± 0.003) indices improved significantly (Po0.05) in the course of the intervention in the 155 children with a decrease of BMI-SDS. There was an additive negative effect of T allele on changes of HOMA-IR (P ¼ 0.041) and QUICKI (P ¼ 0.001) in linear regression analyses adjusted to changes of weight status, age, gender and pubertal stage. Conclusions: Overweight children showed a negative dosage-allele effect per T allele at single-nucleotide polymorphism rs7903146 in TCF7L2 concerning an improvement of insulin resistance and sensitivity after overweight reduction in a lifestyle intervention. This finding further suggests that this polymorphism might be involved in glucose metabolism.

BackgroundGolimumab has shown clinical efficacy and tolerability within its clinical trial program. No systemic outcome data regarding patient-reported outcomes and health economic parameters reflecting the real world use of golimumab in Austria are currently available.MethodsGo Active is a prospective, non-interventional, multi-centre study in Austria. The impact of golimumab therapy on work productivity and activity (WPAI) and quality of life (RAQoL for RA patients, AsQoL for axSpA patients, PsAQoL for PsA patients) is assessed by using patient reported outcomes. Patients (target recruitment: n=320) are followed up to 2 years. For the current interim analysis (data cut-off: 18DEC2017) changes in the primary endpoint from baseline to month 3 were analysed in 167 patients.Results167 patients are included in the current analysis (74 patients with RA, 49 patients with axSpA, and 44 patients with PsA). At study entry, most patients were biological-naïve and employed.Median age at registration was 52 years (patients with RA: 57 years, patients with axSpA: 41 years, and patients with PsA: 44 years). Almost 2/3 of patients were female (84% of patients with RA, 37% patients with axSpA, and 55% of patients with PsA). Most patients were biological-naïve at study entry (77% of all patients, 73% of patients with RA, 80% of patients with axSpA, and 82% of patients with PsA). 42% of patients were not employed (58% of patients with RA, 29% of patients with axSpA, and 30% of patients with SpA); 14% due to incapacity for work (12% of patients with RA, 21% of patients with axSpA, and 16% of patients with SpA) and 54% due to age-related pension (60% of patients with RA, 21% of patients with axSpA, and 69% of patients with SpA). Most of the patients, who worked for pay, worked full time. 159 of all patients and 66 of employed patients completed the WPAI questionnaire at baseline and after 3 months. Overall work productivity improved by −33 (−40 for patients with RA, and −31 for patients with axSpA and PsA) and activity impairment by −30 (−40 for patients with RA and axSpA, and −20 for patients with PsA; figure 1). Quality of life improved by −5 for patients with axSpA and PsA, and by −7 for patients with RA.Abstract FRI0108 – Figure 1WPAI questionnaire – Changes from baseline after 3 months of golimumab treatmentConclusionsThis interim analysis shows that golimumab treatment is effective in improving work productivity, daily activities as well as quality of life already within the first 3 months of treatment in RA, axSpA and PsA patients.Disclosure of InterestC. Dejaco Consultant for: Consulting fees from Merck Sharp and Dohme, Paid instructor for: Remuneration form Merck Sharp and Dohme, Speakers bureau: Merck Sharp and Dohme, T. Mueller: None declared, O. Zamani: None declared, U. Kurtz: None declared, S. Egger: None declared, J. Resch-Passini: None declared, A. Totzauer: None declared, W. Eisterer: None declared, B. Yazdani-Biuki: None declared, T. Schwingenschloegl: None declared, P. Peichl: None declared, A. Kraus: None declare...